The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations
Free accessReview articleFirst published online September, 2010
The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations
Gefitinib and erlotinib, small-molecule tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), were the first molecularly targeted agents to become clinically available for the treatment of non-small cell lung cancer (NSCLC). During the course of their clinical development, it has become clear that the substantial clinical benefit associated with EGFR-TKIs is limited to patients harboring activating mutations of EGFR. Accumulating clinical outcomes in patients with EGFR mutation-positive NSCLC treated with EGFR-TKIs support the notion that this group of individuals constitutes a clinically distinct population. These findings have prompted investigations of the potential role of first-line treatment with EGFR-TKIs in molecularly selected patients, with platinum-based doublet chemotherapy currently being the standard of care for most individuals with advanced NSCLC. This review summarizes the results of recent clinical trials of EGFR-TKIs in selected patients and highlights the efficacy of these drugs in first-line treatment as a form of personalized medicine aimed at improving therapy for advanced NSCLC.
Ando, M., Okamoto, I., Yamamoto, N., Takeda, K., Tamura, K., Seto, T. et al. (2006) Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol24: 2549-2556.
2.
Asahina, H., Yamazaki, K., Kinoshita, I., Sukoh, N., Harada, M., Yokouchi, H. et al. (2006) A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer95: 998-1004.
3.
Inoue, A., Kobayashi, K., Usui, K., Maemondo, M., Okinaga, S., Mikami, I. et al. (2009) First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol27: 1394-1400.
4.
Inoue, A., Suzuki, T., Fukuhara, T., Maemondo, M., Kimura, Y., Morikawa, N. et al. (2006) Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol24: 3340-3346.
5.
Jackman, D.M., Miller, V.A., Cioffredi, L.A., Yeap, B.Y., Janne, P.A., Riely, G.J. et al. (2009) Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res15: 5267-5273.
6.
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J. and Thun, M.J. ( 2009) Cancer statistics, 2009. CA Cancer J Clin59: 225-249.
7.
Kobayashi, K., Inoue, A., Maemondo, M., Sugawara, S., Oizumi, S., Saijo, Y. et al. (2009) First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: a phase III study (002) by North East Japan Gefitinib Study Group. J Clin Oncol27(suppl): abstr 8016.
8.
Lee, J.S., Park, K., Kim, S.-W. et al. (2009) A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. J Thorac Oncol4(Suppl): abstract PRS.4.
9.
Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W. et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med350: 2129-2139.
10.
Mendelsohn, J. and Baselga, J. ( 2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol21: 2787-2799.
11.
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J. et al. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol11: 121-128.
12.
Mok, T.S., Wu, Y.L., Thongprasert, S., Yang, C.H., Chu, D.T., Saijo, N. et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma . N Engl J Med361: 947-957.
13.
Morita, S., Okamoto, I., Kobayashi, K., Yamazaki, K., Asahina, H., Inoue, A. et al. (2009) Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res15: 4493-4498.
14.
Nakagawa, K., Tamura, T., Negoro, S., Kudoh, S., Yamamoto, N., Takeda, K. et al. (2003) Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors . Ann Oncol14: 922-930.
15.
Okabe, T., Okamoto, I., Tamura, K., Terashima, M., Yoshida, T., Satoh, T. et al. (2007) Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. Cancer Res67: 2046-2053.
16.
Okamoto, I. ( 2010) Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy. FEBS J277: 309-315.
17.
Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S. et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science304: 1497-1500.
18.
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I. et al. (2004) EGF receptor gene mutations are common in lung cancers from ‘‘never smokers’’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A101: 13306-13311.
19.
Politi, K., Zakowski, M.F., Fan, P.D., Schonfeld, E.A., Pao, W. and Varmus, H.E. ( 2006) Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev20: 1496-1510.
20.
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C. et al. (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med361: 958-967.
21.
Sequist, L.V., Martins, R.G., Spigel, D., Grunberg, S.M., Spira, A., Janne, P.A. et al. (2008) First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol26: 2442-2449.
22.
Sordella, R., Bell, D.W., Haber, D.A. and Settleman, J. ( 2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science305: 1163-1167.
23.
Sugio, K., Uramoto, H., Onitsuka, T., Mizukami, M., Ichiki, Y., Sugaya, M. et al. (2009) Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations. Lung Cancer64: 314-318.
24.
Sunaga, N., Tomizawa, Y., Yanagitani, N., Iijima, H., Kaira, K., Shimizu, K. et al. (2007) Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer56: 383-389.
25.
Sutani, A., Nagai, Y., Udagawa, K., Uchida, Y., Koyama, N., Murayama, Y. et al. (2006) Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer95: 1483-1489.
26.
Tamura, K., Okamoto, I., Kashii, T., Negoro, S., Hirashima, T., Kudoh, S. et al. (2008) Multicentre prospective phase II trial of gefitinib for advanced nonsmall cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403) . Br J Cancer98: 907-914.
27.
Yang, C.H., Shih, J.Y., Chen, K.C., Yu, C.J., Yang, T.Y., Lin, C.P. et al. (2006) Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer. Cancer107: 1873-1882.
28.
Yoshida, K., Yatabe, Y., Park, J.Y., Shimizu, J., Horio, Y., Matsuo, K. et al. (2007) Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. J Thorac Oncol2: 22-28.
